Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human DAB2IP Antibodies:
anti-Rat (Rattus) DAB2IP Antibodies:
anti-Mouse (Murine) DAB2IP Antibodies:
Go to our pre-filtered search.
Human Polyclonal DAB2IP Primary Antibody for IP, WB - ABIN440620
Cook, Kim, Terao, Gotoh, Higuchi: Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. in Cell death & disease 2012
These findings suggest that DAB2IP is a direct target of miRNA-556-3p, and endogenous miRNA-556-3p expression shows inverse correlation with simultaneous DAB2IP expression in bladder cancer (BC)tissues and cells. miRNA-556-3p functions as a tumor promoter in tumorigenesis and metastasis of BC by targeting DAB2IP
Low DAB2IP expression is associated with neoplasms.
Results identified PRRT2 (show PRRT2 Antibodies) and DAB2IP to be frequently mutated in all different cancer cell line types. Further analysis showed that both genes were also frequently mutated in colorectal and endometrial cancer patient samples.
Data suggest that DAB2IP CpG1 methylation is a practical and repeatable biomarker for renal cell carcinoma (show MOK Antibodies) (ccRCC), which can provide prognostic value that complements the current staging system.
PROX1 overexpression in DAB2IP-deficient prostate cancer cells could enhance the accumulation of HIF1alpha protein by inhibiting ubiquitin pathway and then consequently induce an epithelial-mesenchymal transition response.
Study shows that up to 62% of luminal B cancers have lost expression of at least one of the DAB2IP and RASAL2 (show RASAL2 Antibodies) genes. However, the tumors that have lost both genes frequently present as advanced disease and are more likely to recur. Importantly, the report provide evidence that DAB2IP and RASAL2 (show RASAL2 Antibodies) can individually function as tumor suppressors in breast cancer.
The low expression of DAB2IP in bladder carcinoma cells was related to drug resistance.
Down-regulation of DAB2IP correlated negatively with hnRNPK (show HNRNPK Antibodies) and MMP2 (show MMP2 Antibodies) expressions in CRC (show CALR Antibodies) tissues. In conclusion, our study elucidates a novel mechanism of the DAB2IP/hnRNPK (show HNRNPK Antibodies)/MMP2 (show MMP2 Antibodies) axis in the regulation of CRC (show CALR Antibodies) invasion and metastasis, which may be a potential therapeutic target.
DAB2IP appears to be a new prognostic/predictive marker for metastatic renal cell cancer (mRCC) patients, and its function provides a new insight into the molecular mechanisms of drug resistance to mTOR (show FRAP1 Antibodies) inhibitors, which also can be used to develop new strategies to overcome drug-resistant mRCC.
Along with the reduction of ovarian cancer-2/disabled homolog 2 (DOC-2 (show DAB2 Antibodies)/DAB2) interactive protein (DAB2IP) expression, EGR-1 (show EGR1 Antibodies) gene was upregulated in FI-treated cells. On the other hand, downregulation of EGR-1 (show EGR1 Antibodies) gene expression sensitized radioresistant cells to IR accompanied by DAB2IP overexpression and STAT3 (show STAT3 Antibodies) inactivation. In addition, NF-kappaB (show NFKB1 Antibodies) inhibitor, BAY11-7082 enhanced resistant cells' radiosensitivity and chemos...
DAB2IP loss reprograms intracellular signal transduction and anti-apoptotic gene expression, which potentiates prostate cancer cell survival from androgen deprivation therapy-induced cell death.
Germ cell-specific or Sertoli cell-specific deletion of Aip1 gene each led to significant defects in germ cell migration after postnatal day 4 or 5, accompanied by elevated levels of actin filaments (F-actin) in the affected cells.
Cor1B, Cof1 and AIP1 work in concert through a temporally ordered pathway to induce highly efficient severing and disassembly of actin filaments.
results suggest that Dab2IP plays an important role in the migration and positioning of a subpopulation of later-born (layers II-IV) neurons, likely through the regulation of Rap1 and integrin signaling.
Our data reveal that AIP1 (show PDCD6IP Antibodies), by inhibiting VEGFR2 (show KDR Antibodies)-dependent signaling in tumor niche, suppresses tumor EMT (show ITK Antibodies) switch, tumor angiogenesis, and tumor premetastatic niche formation to limit tumor growth and metastasis.
AIP1 (show PDCD6IP Antibodies) was elevated in the brain of AD Tg2576 mice. Abeta1-42 treatment induced the interaction of AIP1 (show PDCD6IP Antibodies) and ASK1 (show MAP3K5 Antibodies), which led to dissociation of ASK1 (show MAP3K5 Antibodies) and 14-3-3 (show YWHAQ Antibodies).
site-specific methylation of mDab2ip gene during cerebellar development may play a role in inclusion of exon 5, resulting in a Dab2ip transcript variant that encodes a full pleckstrin (show PLEK Antibodies) homology (PH) domain.
Study showed that DAB2IP can be functionally inactivated by physical interaction with mutant p53 (show TP53 Antibodies) proteins with implications for the response of cancer cells to inflammatory cytokines.
DAB2IP is a unique intrinsic androgen receptor (show AR Antibodies) modulator in normal cells, and likely can be further developed into a therapeutic agent for rpostate cancer.
DAB2IP is a Ras (MIM 190020) GTPase-activating protein (GAP) that acts as a tumor suppressor. The DAB2IP gene is inactivated by methylation in prostate and breast cancers (Yano et al., 2005
DAB2 interacting protein
, ASK-interacting protein 1
, ASK1-interacting protein 1
, DAB2 interaction protein
, DAB2-interacting protein
, DOC-2/DAB-2 interactive protein
, DOC-2/DAB2 interactive protein
, disabled homolog 2-interacting protein
, nGAP-like protein
, apoptosis signal-regulating kinase 1-interacting protein 1
, disabled homolog 2 interacting protein
, DOC2/DAB2 interactive protein
, disabled 2 interacting protein long form